CooperCompanies' 52-Week Low Is a Re-Rating, Not a Bargain

A stock that loses a fifth of its value in one session is usually sold as a moment. CooperCompanies (COO) — the contact-lens and women's-health maker behind CooperVision and CooperSurgical — did exactly that on September 10, touching a 52-week low near $51 early in the day before the headline "guidance adjustments" did the explaining. But the story is less the swing and more what the swing exposes: the business was already stalling, and the numbers the company now stands behind are much worse than the ones it gave three months ago.

The reason a dip buyer should slow down is the shape of the guidance cut itself. Full-year fiscal 2026 revenue was trimmed to a $3.33–3.38 billion range from $3.46–3.53 billion — a roughly 4% cut at the midpoint. Earnings per share went to $2.70–2.80 from $3.05–3.15, about an 11% cut. When the earnings cut runs nearly three times deeper than the revenue cut, the problem is not just weaker demand that volume solves later. It is margin — the incremental cost, the mix, the expense — eating the lower line faster than sales.

That read is confirmed by what the third quarter actually printed. Revenue rose just 1% year over year to $1.066 billion, on 1% organic growth. CooperVision was essentially flat at $717 million, pressured by planned U.S. channel inventory reductions. CooperSurgical grew 3% organically to $349 million — solidly below the double-digit growth investors once paid up for, and a reason analysts flagged the segment as a laggard versus peers rather than the growth engine the stock was never priced for anyway.

The cheap-looking multiple is a trap

On trailing earnings, this looks like a value stock. At the current price near $54, COO trades around 18x trailing earnings — well under Alcon's roughly 50x and Align Technology's mid-20s in the same vision-care/mouth-care neighborhood. Pair that with a 13.7x trailing EV/EBITDA and the reflexive read is "the market has overcorrected."

That read only holds if the earnings the market is underwriting are the earnings that are actually coming. They are not. On the reduced guidance midpoint, the shares cost roughly 20x the earnings the company now says it will produce this fiscal year — meaning the forward multiple is higher than the trailing one. A forward P/E that exceeds the trailing P/E is the signature of a reset in the other direction: not a discount on future profits, but a discount on past ones the company has already walked away from. Matching the multiple to the reset stream converts a supposed deep-value entry into a roughly quality-priced stake in a business growing about 1%.

The rest of the factor stack backs up the red flag rather than softening it. Growth is single-digit and flat quarter over quarter. Profitability is thin for a "quality" medical franchise — return on invested capital in the mid-single digits and an operating margin near 12% on a 65% gross margin, which is a lot of gross profit leaking out before the bottom line. Momentum has collapsed: the stock is down about 22% in five days and a third on the year, trading below both its 50- and 200-day averages with a hugely oversold reading. None of that is a buy signal on its own; momentum is a timing tool, and a heavily oversold bounce is not the same as an improving report card.

Hold is not Sell, and the missing catalyst matters

There is one offsetting factor worth separating out, because it is easy to bury in the noise: the balance sheet is the sturdiest line in the file. Net debt sits near $2.4 billion against roughly $8.3 billion of equity — a moderate 0.3 debt-to-equity — and free cash flow rose sharply year over year, well north of half a billion dollars. Solvency is not the problem here. Safety grades support a Hold; they do not manufacture a fresh Buy into a weakening report card.

It also matters that the company chose to keep CooperSurgical. The strategic review concluded with CooperCompanies keeping the division rather than selling it — a decision BNP Paribas analysts suggested helped knock the shares down, and a direct hit to any thesis that owned the stock partly for the optionality of a divestiture unlocking value. For those investors, removing the exit changes the case in a way no trading dip fixes.

None of this makes the stock a sell for someone who already holds it — a rating cooling from Buy to Hold as the report card degrades is the process working, not the business breaking. For a buyer without a position, the disciplined read is different. What you are watching for is the improving report card, the move from weak back to decent: CooperVision's U.S. channel destocking normalizing enough for contact-lens revenue to re-accelerate, or margin stabilization showing up as upward revisions instead of downward ones. Buy the evidence that the report card has turned, not the bounce. In the meantime, an 18x trailing multiple on a 1%-growing business that just gave back a quarter of its value is a bargain only if you forget what the company just told you about next year.